Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

664
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
664
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

904
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
904
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

740
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
740
Autoimmune Disorders01:29

Autoimmune Disorders

2.2K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.2K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

624
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
624
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

6.1K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severe Osteoporosis in a Young Woman With Type 1 Diabetes and Pancreatic Exocrine Insufficiency.

Case reports in endocrinology·2026
Same author

Effects of rice bran arabinoxylan compound on quality of life of cancer patients during active treatment: a randomised placebo-controlled pilot trial.

Scientific reports·2026
Same author

Regression of Post-Essential Thrombocythaemia Myelofibrosis with Intermittent Hydroxyurea Therapy: A Case Report.

Journal of clinical medicine·2025
Same author

Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera.

Journal of clinical medicine·2024
Same author

Regression of Intermediate-High Risk Monoclonal Gammopathy of Undetermined Significance (MGUS) With Long-term Use of Curcumin: A Case Report.

Integrative cancer therapies·2024
Same author

Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma.

Journal of hematology·2023

Related Experiment Video

Updated: Mar 28, 2026

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

9.5K

B-Cell Disorders and Curcumin.

Terry Golombick1, Terrence H Diamond1, Arumugam Manoharan2

  • 11 St George Hospital, Sydney, New South Wales, Australia.

Integrative Cancer Therapies
|December 18, 2015
PubMed
Summary

Early intervention with curcumin may prolong survival for patients with early hematological malignancies, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. This natural compound shows potential in delaying disease progression in select individuals.

Keywords:
curcuminintegrative medicinemonoclonal gammopathy of undetermined significancesmoldering myelomastage 0/1 chronic lymphocytic leukemia

More Related Videos

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
06:39

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis

Published on: October 27, 2023

1.6K
Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin
10:15

Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin

Published on: November 1, 2019

13.5K

Related Experiment Videos

Last Updated: Mar 28, 2026

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells
12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

9.5K
Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
06:39

Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis

Published on: October 27, 2023

1.6K
Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin
10:15

Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin

Published on: November 1, 2019

13.5K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Early hematological malignancies like monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and early chronic lymphocytic leukemia (CLL) represent a significant clinical challenge.
  • Current management strategies often involve active surveillance, but the potential for early intervention is an area of active research.
  • Curcumin, a compound found in turmeric, has demonstrated various biological activities, including anti-inflammatory and anti-cancer properties in preclinical studies.

Purpose of the Study:

  • To evaluate the potential of early curcumin intervention in patients with specific early-stage hematological malignancies.
  • To assess the impact of curcumin on patient survival and disease progression in this cohort.
  • To explore curcumin as a therapeutic option for delaying the advancement of MGUS, SMM, and early CLL.

Main Methods:

  • Review of clinical studies involving patients diagnosed with early hematological malignancies.
  • Analysis of data pertaining to patients who received early intervention with curcumin.
  • Assessment of survival rates and time to disease progression in the studied patient groups.

Main Results:

  • Clinical studies suggest that early intervention with curcumin may be associated with prolonged survival in some patients.
  • Curcumin treatment appears to delay disease progression in a subset of individuals with early hematological malignancies.
  • The findings indicate a potential benefit of curcumin in managing MGUS, SMM, and early CLL.

Conclusions:

  • Early intervention with curcumin shows promise as a strategy to improve outcomes in patients with early hematological malignancies.
  • Curcumin may serve as a valuable agent in delaying the progression of conditions such as MGUS, SMM, and early CLL.
  • Further research is warranted to fully elucidate the role of curcumin in the management of these hematological disorders.